A clinical trial of the rheumatoid arthritis drug Kevzara as a treatment for the coronavirus has started.
Sanofi SA and partner
Regeneron Pharmaceuticals Inc have started a clinical
trial of their rheumatoid arthritis drug Kevzara as a treatment
for the coronavirus, the companies said on Monday.
Enrolments for the mid-to-late stage trial will begin
immediately, and the companies anticipate the trial will test up
to 400 patients.
Kevzara is an infection-fighting protein known as monoclonal
antibody.
Regeneron in February announced a partnership with the US Department of Health and Human Services to develop a coronavirus
treatment, and had said it would focus on monoclonal antibodies.
* For the latest on the Covid-19 outbreak visit IOL’s #Coronavirus trend page.
** If you think you have been exposed to the Covid-19 virus, please call the 24-hour hotline on 0800 029 999
*** Receive IOL’s top stories via Whatsapp by sending your name to 0745573535
**** Follow IOL on Facebook
and Twitter
to join the conversation and stay updated with the latest news.
Reuters
